Skip to content
AnalystLens

Insmed Annual Report (Amendment), Year Ended Dec 31, 2003

Filing Date
Filed August 25, 2004
Period End
December 31, 2003
Security
INSM
In the record · 2016–202610-K1110-Q338-K134

INSM filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Oct ’16Oct ’16
  2. FY2018 annual report10-K · Feb ’19Feb ’19
  3. Leadership change8-K · Jun ’21Jun ’21
  4. Leadership change8-K · May ’25May ’25

01—Abstract

Summary

Summary of the 10-K/A filed August 25, 2004. Cited figures are marked; the original filing is the authoritative source.

Insmed Incorporated, a Virginia corporation headquartered in Glen Allen, Virginia, filed this Amendment No. 1 on Form 10-K/A on August 25, 2004, for the fiscal year ended December 31, 2003.

The original annual report was filed on March 12, 2004. The amendment is limited in scope. Its stated purpose is to correct the inadvertent exclusion of Exhibit A to the License Agreement dated as of January 19, 2004, between the company and Fujisawa Pharmaceutical Co., Ltd., which was filed as Exhibit 10.18 to the original report.

The filing restates Exhibit 10.18 in its entirety and states that it has not been updated for events after the original filing date. The cover page reports an aggregate market value of $89,308,519a held by non-affiliates as of June 30, 2003, based on the Nasdaq National Market closing price, and 38,394,994 shares of common stock outstanding as of February 29, 2004. Part III information is incorporated by reference from the definitive proxy statement.

02—Key points

Key Highlights

  1. Form 10-K/A (Amendment No. 1) for the fiscal year ended December 31, 2003, filed August 25, 2004
  2. Amendment purpose: to add the omitted Exhibit A to the January 19, 2004 License Agreement with Fujisawa Pharmaceutical Co., Ltd., filed as Exhibit 10.18
  3. Exhibit 10.18 is amended and restated in its entirety in this filing
  4. Non-affiliate market value of $89,308,519 as of June 30, 2003, based on Nasdaq National Market prices
  5. 38,394,994 shares of common stock, $.01 par value, outstanding as of February 29, 2004
  6. Original Form 10-K was filed March 12, 2004; this amendment is not updated for later events
  7. Part III information is incorporated by reference from the definitive proxy statement

03—Questions

Frequently Asked Questions

  1. Why was this amended filing made?

    The company filed this amendment solely to correct the inadvertent exclusion of Exhibit A to the License Agreement with Fujisawa Pharmaceutical Co., Ltd., which was filed as Exhibit 10.18 to the original Form 10-K.

  2. What agreement does the amended exhibit relate to?

    It relates to the License Agreement dated as of January 19, 2004, between Insmed Incorporated and Fujisawa Pharmaceutical Co., Ltd. This filing restates Exhibit 10.18 in its entirety.

  3. Does this amendment update the company's financial or business information?

    No. The amendment states that it has not been updated to reflect any events that occurred after the day the original Form 10-K was filed.

  4. How many shares were outstanding and what was the non-affiliate market value?

    As of February 29, 2004, there were 38,394,994 shares of common stock outstanding. The aggregate market value held by non-affiliates was $89,308,519 as of June 30, 2003, based on the Nasdaq National Market closing price on that date.

04—Continue

← View all 10-K filings